You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ZAROXOLYN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ZAROXOLYN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00649051 ↗ Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg Completed Mylan Pharmaceuticals Phase 1 2002-12-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions.
NCT00649181 ↗ Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg Completed Mylan Pharmaceuticals Phase 1 2003-10-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose administration under fasting conditions.
NCT00650195 ↗ Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg Completed Mylan Pharmaceuticals Phase 1 2004-02-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions.
NCT00904488 ↗ Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Terminated University of Illinois at Chicago Phase 4 2008-10-01 The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.
NCT00904488 ↗ Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Terminated Virginia Commonwealth University Phase 4 2008-10-01 The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.
NCT00904488 ↗ Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Terminated University of North Carolina, Chapel Hill Phase 4 2008-10-01 The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.
NCT02606253 ↗ Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Completed Vanderbilt University Phase 4 2016-02-01 Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with hypervolemia Specific Aims: 1. Compare the 48-hour weight change of either intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in decompensated heart failure 2. Compare the adverse effects of electrolyte depletion and renal function changes between intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure 3. Pharmacoeconomic analysis of the direct costs of intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure The investigators will conduct a dual center, randomized, double-blind, double-dummy, parallel design trial comparing: oral metolazone, intravenous chlorothiazide, or oral tolvaptan, in combination with loop diuretics in 60 patients hospitalized for hypervolemic decompensated heart failure and displaying loop diuretic resistance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZAROXOLYN

Condition Name

Condition Name for ZAROXOLYN
Intervention Trials
Healthy 3
Heart Failure Acute 2
Heart Failure 2
Heart Failure With Reduced Ejection Fraction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZAROXOLYN
Intervention Trials
Heart Failure 4
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZAROXOLYN

Trials by Country

Trials by Country for ZAROXOLYN
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ZAROXOLYN
Location Trials
West Virginia 2
Maryland 1
Virginia 1
Tennessee 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZAROXOLYN

Clinical Trial Phase

Clinical Trial Phase for ZAROXOLYN
Clinical Trial Phase Trials
Phase 4 4
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZAROXOLYN
Clinical Trial Phase Trials
Completed 4
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZAROXOLYN

Sponsor Name

Sponsor Name for ZAROXOLYN
Sponsor Trials
Mylan Pharmaceuticals 3
University of Maryland, Baltimore 1
University of Illinois at Chicago 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZAROXOLYN
Sponsor Trials
Other 7
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.